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Abstract
Telomere length variation has been associated with increased risk of several types of tumors, and telomere shortening, with
genetic anticipation in a number of genetic diseases including hereditary cancer syndromes. No conclusive studies have
been performed for Lynch syndrome, a hereditary colorectal cancer syndrome caused by germline mutations in the DNA
mismatch repair genes. Here we evaluate telomere length in Lynch syndrome, both as a cancer risk factor and as a
mechanism associated with anticipation in the age of cancer onset observed in successive generations of Lynch syndrome
families. Leukocyte telomere length was measured in 244 mismatch repair gene mutation carriers from 96 Lynch syndrome
families and in 234 controls using a monochrome multiplex quantitative PCR method. Cancer-affected mutation carriers
showed significantly shorter telomeres than cancer-free mutation carriers. In addition, cancer-affected carriers showed the
most pronounced shortening of telomere length with age, compared with unaffected carriers. The anticipation in the age of
cancer onset observed in successive generations was not associated with telomere shortening, although, interestingly, all
mother-son pairs showed telomere shortening. In conclusion, cancer-affected mismatch repair gene mutation carriers have
distinct telomere-length pattern and dynamics. However, anticipation in the age of onset is not explained by telomere
shortening. Pending further study, our findings suggest that telomere attrition might explain the previously reported
dependence of cancer risk on the parent-of-origin of mismatch repair gene mutations.
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Introduction
Lynch syndrome (LS) (MIM 120435) is the most common
hereditary syndrome that predisposes to colorectal cancer (CRC)
and other extracolonic tumors, accounting for 2%–5% of the total
burden of CRC. It is caused by germline mutations in the DNA
mismatch repair (MMR) genes MLH1 (MIM 120436), MSH2
(MIM 609309), MSH6 (MIM 600678) and PMS2 (MIM 600259),
as well as in EPCAM (MIM 185535). There is large phenotypic
variation in the age of onset among and within families [1,2].
Progressively earlier age of cancer onset in successive generations
has been reported [3–10]. However, the underlying molecular
mechanisms of both the overall phenotypic variation and the
anticipation in the age of onset are still unknown.
Telomere shortening has gained considerable interest as a
potential biomarker of cancer risk and as a mechanism associated
with genetic anticipation. Moreover, we have recently shown that
a common genetic variant located in the telomerase gene (hTERT;
MIM 187270) increases cancer risk in LS patients at early ages,
and that this SNP is associated with shortened telomere length in
cancer-affected MMR gene mutation carriers [11]. Telomeres
consist of multiple short repeats (TTTAGG) at the ends of
chromosomes and protect them against large-scale genomic
rearrangements. In most somatic cells, telomeres shorten with
each replication cycle, eventually leading to cellular senescence or
apoptosis. Interestingly, telomere length anomaly appears to be
one of the earliest and most prevalent genetic alterations in the
process of malignant transformation [12,13]. Given the proposed
role of telomere shortening in early processes of carcinogenesis,
attention has been directed to its potential role as a cancer risk
biomarker. With this purpose, a number of retrospective and
prospective observational studies have been conducted, although
results are inconsistent among studies and tumor types [14–16].
With respect to CRC, despite the conflicting results obtained in
retrospective studies, prospective studied have not found a
convincing association between leukocyte telomere length and
CRC risk [16–18].
Telomere length attrition has also been proposed as a
mechanism of anticipation in different inherited diseases, being
associated with early onset and/or severity of disease in genetic
disorders such as dyskeratosis congenita [19–21], Li-Fraumeni
[22,23], and familial breast and ovarian cancer [24,25].
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Here we aim to elucidate the role of telomere length in LS-
associated cancer risk and to study its implication in anticipation in
the age of onset observed in successive generations of LS families.
Materials and Methods
Ethics statement
Written informed consent was obtained from all subjects. The
study received the approval of the IDIBELL Ethics Committee
(ref. PR221/09).
Study participants
A total of 388 individuals, 244MMR gene mutation carriers and
144 non-carriers, from 96 LS families were included in the study.
They were assessed through the Hereditary Cancer Program at
the Catalan Institute of Oncology, ICO-IDIBELL, from 1998 to
2012. MMR gene mutation analysis was performed on genomic
DNA extracted from peripheral blood. Large genomic alterations
in the genes were studied using Multiplex Ligation-dependent
Probe Amplification (MLPA) (SALSA MLPA Kits, MRC-
Holland, The Netherlands). Mutation screening was carried out
by direct sequencing after PCR amplification (primers and
conditions available upon request). Ninety cancer-free individuals
were included as controls. All individuals are of Caucasian origin.
Informed consent was obtained from all subjects, although data
were analyzed anonymously. Table 1 shows a summary of the
genetic and clinical characteristics of the groups studied.
Cases and controls were recruited from the same homogeneous
population, and storage and DNA extraction from peripheral
blood were performed at the same facility and using the same
extraction methods. We have observed that blood DNA samples
from different sources (i.e., extracted at different laboratories,
using different extraction methods, etc.) show large non-genetic
variation in telomere length (data not shown). Thus, only samples
(cases and controls) that underwent the exact same DNA
extraction protocol (Flexigene DNA kit, Qiagen, Hilden, Ger-
many) performed by the personnel of the Unit of Molecular
Diagnostics of the Hereditary Cancer Program at ICO-IDIBELL,
and that were stored under the same conditions, were included in
the study, as recommended by Prescott et al. for retrospective
studies [16].
Telomere length assessment
Telomere length quantification was performed using the
monochrome multiplex quantitative PCR method described by
Cawthon et al. [26], which has been found to provide greater
consistency than other methods used to measure telomere length
[17]. The assays were performed using the Quantifast SybrGreen
PCR Master Mix (Qiagen, Hamburg, Germany), beta-globin as
single copy gene, and the LightCycler 480 real-time PCR
detection system (Roche Diagnostics GmbH, Mannheim, Ger-
many). All samples were assayed in triplicate. A standard curve
with 7 concentrations spanning an 81-fold rage (60 ng, 40 ng,
20 ng, 6.7 ng, 4 ng, 2.2 ng and 0.74 ng), also in triplicate, of an
anonymous standard DNA (healthy and cancer-free 45 year-old
individual) was included in every 384-well plate. Good replicates of
the standard curves (for telomeres (T) and single copy gene (S)) and
subsequent fitted linear regression lines were obtained among
plates. Whenever possible, equal numbers of samples from
different clinical groups were run in each 384-well plate. The
relative telomere length (RTL) value for each sample was
calculated according to the standard lines (for T and S) of the
corresponding plate. Therefore, the value obtained was relative to
the value of the anonymous standard DNA in the same plate
(inter-run calibration). The average telomere length of each
sample is expected to be proportional to its RTL.
Statistical analyses
Shortening of telomere length is observed with increasing age in
cancer-free individuals [27]. In our control set (controls plus non-
carriers, n = 234), RTL was inversely correlated with age
(Pearson’s correlation r =20.187; p = 0.004). As previously
described, RTL measurements were adjusted for age using the
line of best fit for controls [25]. Thus, the difference between the
observed and the predicted value was calculated for each sample
and is represented as ‘‘age-adjusted RTL’’. There were no
Table 1. Genetic and clinical characteristics of the studied groups.
Lynch syndrome families (n =96)
Controls (n=234)
MMR gene mutation carriers (244) Non-carriers Unrelated controls
*Cancer Cancer-free
N 144 100 144 90
MMR gene mutated: n (%) MLH1: 87 (60.4) MLH1: 62 (62.0) - -
MSH2: 42 (29.2) MSH2: 29 (29.0) - -
MSH6: 9 (6.3) MSH6: 9 (9.0) - -
PMS2: 5 (3.5) PMS2: 0 - -
EpCAM: 1 (0.7) EpCAM: 0 - -
Median age at blood draw (6 SD) 51.5 (613.4) 35.0 (611.5) 42.0 (614.9) 41.5 (615.1)
Sex: n (%) M: 74 (51.4) M: 40 (40.0) M: 64 (44.4) M: 28 (31.1)
F: 70 (48.6) F: 60 (60.0) F: 80 (55.6) F: 62 (68.9)
Median age at cancer diagnosis (6 SD) 43.0 (612.9)
N: number of subjects; SD: standard deviation; M: male; F: female.
*Cancer: Individual affected with a LS-associated cancer: CRC and/or cancer of the endometrium, ovary, stomach, small bowel, hepatobiliary tract, pancreas, upper uro-
epithelial tract or brain.
doi:10.1371/journal.pone.0061286.t001
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telomere length differences between sexes (data not shown);
therefore, sex was not included as a confounding factor in the
statistical tests.
Differences in age-adjusted telomere lengths were analyzed
using the Wilcoxon rank sum test (Mann-Whitney U). Pearson’s
test was used to assess the correlation between telomere length and
age (telomere length dynamics). To measure the significance of the
difference between two correlation coefficients (Pearson’s r),
Fisher’s r-to-z transformation was performed. Anticipation was
represented by Kaplan-Meier curves and the differences between
survival curves were studied using a log-rank test. Proportions
were compared by Fisher’s exact test (expected cell count ,5) or
Chi-square. All tests were two-sided and p-values below 0.05 were
considered statistically significant. The analyses were performed
using R.
Figure 1. Age-adjusted relative telomere length. In subjects belonging to LS families: MMR gene mutation carriers affected with cancer
(median: 20.131), MMR gene mutation carriers with no diagnosed cancer (median: 20.079) and cancer-free non-carriers (median: 20.091); and in
cancer-free controls (median: 20.097). The boxes represent the interquartile range of distributions (25th and 75th percentiles); the horizontal lines
within the boxes, the medians; and the vertical lines, the 5th and 95th percentiles.
doi:10.1371/journal.pone.0061286.g001
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Results
Telomere length and shortening dynamics
Relative telomere length was assessed in 244 MMR gene
mutation carriers, both cancer-affected (n = 144) and unaffected
(n = 100), and in 234 controls, including non-carriers from the
same LS families (n = 144) and unrelated cancer-free controls
(n = 90) (Figure 1). Relative telomere length values were adjusted
for age as indicated in the Materials and Methods section (see
statistical analyses). We found that among mutation carriers,
cancer cases had significantly shorter age-adjusted telomeres than
unaffected individuals (p = 0.032). It is worth noting that
unaffected mutation carriers have longer telomeres than unaffect-
ed controls: a significant increase of the fourth quartile (longest
telomeres) is observed in cancer-free MMR mutation carriers
(36.0%) compared with controls (21.8%; p= 0.010) and cancer-
affected carriers (20.1%; p= 0.009) (Figure 2).
As expected, the negative slope of the linear regression line that
best fit the RTL data for the controls indicated that telomere
length shortened with age (Pearson’s correlation coefficient
r =20.187; p= 0.004); the same was observed for the MMR gene
mutation carriers (r =20.297; p = 2.3761026). No differences
were observed between both groups (p = 0.204) (Figure 3A).
Among MMR gene mutation carriers, cancer-affected individuals
showed faster telomere attrition with age (r =20.344;
p = 2.461025) than cancer-free carriers (r =20.094; p = 0.351)
(for the difference, p = 0.045) (Figure 3B). No differences were
observed between MSH2 (r =20.446; p= 0.003) and MLH1
(r =20.318; p = 0.003) mutation carriers (for the difference,
p = 0.435).
Figure 2. Distribution of cancer-affected and cancer-free MMR gene mutation cases and controls by quartiles of age-adjusted
telomere length.
doi:10.1371/journal.pone.0061286.g002
Figure 3. Correlation of relative telomere length (RTL) with age at blood draw. (A) RTL distribution as a function of age for controls
(n = 234; white circles) and all MMR gene mutation carriers (n = 244; black circles). (B) RTL distribution as a function of age for cancer-affected MMR
gene mutation carriers (n = 144; black circles) and cancer-freeMMR gene mutation carriers (n = 100; crossed circles). r: Pearson’s correlation coefficient.
doi:10.1371/journal.pone.0061286.g003
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Telomere length and anticipation in the age of cancer
onset
The occurrence of age anticipation in cancer-affected mutation
carriers was analyzed in 59 LS families, harbouring MLH1 (32
families), MSH2 (20 families) and MSH6 (7 families) mutations.
The distribution of age at cancer diagnosis in parents and children
showed a consistent shift to early ages in children (p= 2.561027)
(Figure 4). On average, cancer was diagnosed 12 years earlier in
children (Table 2). Five out of 65 parents and 3 out of 30 children
had been diagnosed with cancer (1st LS-related cancer diagnosed)
during the follow-up period or clinical surveillance of mutation
carriers. Their exclusion from the analysis did not alter the results
(data not shown). The information available from polyp removal
and surveillance time across generations was incomplete and was
not included in the study.
The relationship between telomere length and anticipation in
LS was next investigated. No differences between parents and
children were observed in cancer-affected MMR gene mutation
carriers (p = 0.867) (Figure 5). Similarly, no association was found
when MLH1 and MSH2 gene mutation cases were analyzed
Figure 4. Anticipation in age of cancer onset in LS families.
Kaplan-Meier curves and associated p-values showing the differences in
age of cancer onset between parents and children, all of them cancer-
affected MMR gene mutation carriers.
doi:10.1371/journal.pone.0061286.g004
Figure 5. Changes in age-adjusted RTL between parents and
children. Box plots representing age-adjusted RTL distributions in
cancer-affected parents and children with MMR gene mutations. The
boxes represent the interquartile range of distributions (25th and 75th
percentiles); the horizontal lines within the boxes, the medians; and the
vertical lines, the 5th and 95th percentiles.
doi:10.1371/journal.pone.0061286.g005
Table 2. Differences in average age of onset of cancer (1st LS-related tumor diagnosed) between parents and children with Lynch
syndrome.
Parents Children
N Age of onset N Age of onset
Mean age
difference t-statistic p-value
Median Mean SD Median Mean SD
All 65 51.0 50.9 12.8 30 38.0 38.9 7.6 12.0 4.74 7.561026
MLH1 36 50.5 50.9 11.7 20 38.0 38.0 6.8 12.9 4.53 3.361025
MSH2 21 53.0 51.4 15.4 7 37.0 41.4 10.4 10 1.59 0.124
MSH6 8 44.0 49.6 11.5 2 37.5 37.5 6.4 12.1 1.40 0.200
N: number of subjects; SD: standard deviation.
doi:10.1371/journal.pone.0061286.t002
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separately (Figure S1). Next, we compared changes in telomere
length in individual parent-child pairs (Table 3). In all instances,
the child was diagnosed with cancer at an earlier age than the
corresponding LS parent. Children showed shorter telomeres than
their parents in 10 out of 21 (47.6%) cancer-affected carrier pairs,
in 6 out of 9 (66.7%) cancer-free carrier pairs, and in 1 out of 3
(33.3%) cancer-free non-carriers evaluated, although the these
differences were not statistically significant (p = 0.562).
Anticipation was associated with shorter telomeres in all (5/5)
mother-son cancer-affected MMR gene mutation carriers, whereas
this association was only observed in 31% (5/16) of the other
cancer-affected carrier pair combinations (p = 0.012) (Table 3).
Table 3. Age-adjusted RTL and anticipation in age at cancer diagnosis in parent-child pairs.
PARENT CHILD
Family MMR gene Tumor *Age Sex Age-adjusted RTL Tumor *Age Sex
Age-adjusted
RTL **Telchild,Telparent
Cancer-affected carriers
Fam-1 MSH2 CRC 73 F 20.172 CRC 45 M 20.216 yes
Fam-2 MSH2 EC 78 F 0.167 CRC 55 F 20.339 yes
Fam-2 MSH2 CRC 55 F 20.339 CRC 33 F 20.188 no
Fam-2 MSH2 EC 78 F 0.167 CRC 55 F 20.217 yes
Fam-3 MSH2 CRC 60 F 20.098 CRC 35 F 0.407 no
Fam-4 MLH1 CRC 53 F 20.143 CRC 40 (in surv) F 0.372 no
Fam-4 MLH1 CRC 53 F 20.143 CRC 32 M 20.521 yes
Fam-5 MLH1 CRC 48 M 0.328 CRC 35 M 0.567 no
Fam-6 MLH1 CRC 52 F 0.635 CRC 34 F 0.736 no
Fam-7 MLH1 CRC 50 F 0.388 CRC 55 (in surv) F 20.103 yes
Fam-8 MLH1 CRC 51 M 20.240 CRC 28 F 20.022 no
Fam-9 MLH1 CRC 51 M 0.332 CRC 45 F 0.178 yes
Fam-10 MLH1 CRC 33 M 20.398 CRC 24 F 20.154 no
Fam-11 MLH1 CRC 69 (in surv) M 20.298 CRC 37 F 20.206 no
Fam-11 MLH1 CRC 69 (in surv) M 20.298 CRC 41 (in surv) F 20.247 no
Fam-12 MLH1 CRC 66 F 20.014 CRC 47 M 20.373 yes
Fam-12 MLH1 CRC 66 F 20.014 CRC 39 M 20.322 yes
Fam-12 MLH1 CRC 66 F 20.014 CRC 40 M 20.103 yes
Fam-13 MLH1 CRC 60 F 20.081 CRC 38 F 20.030 no
Fam-14 MLH1 CRC 77 F 20.235 CRC 38 F 20.076 no
Fam-15 MSH6 UC 69 M 20.032 CRC 33 M 20.478 yes
Cancer-free carriers
Fam-16 MLH1 - 48 M 20.347 - 24 M 20.327 no
Fam-16 MLH1 - 48 M 20.347 - 25 F 20.688 yes
Fam-17 MLH1 - 47 M 20.121 - 27 F 20.387 yes
Fam-18 MLH1 - 64 F 20.244 - 36 M 20.095 no
Fam-18 MLH1 - 64 F 20.244 - 39 M 20.134 no
Fam-19 MLH1 - 45 F 0.048 - 18 M 20.202 yes
Fam-20 MLH1 - 78 M 0.399 - 37 F 20.186 yes
Fam-21 MSH2 - 47 F 0.552 - 22 M 20.021 yes
Fam-22 MSH6 - 65 F 20.230 - 30 M 20.300 yes
***Cancer-free non-carriers
Fam-23 - - 71 F 20.336 - 45 M 0.000 no
Fam-20 - - 74 F 20.284 - 50 M 20.181 no
Fam-24 - - 85 F 20.268 - 53 F 20.432 yes
MMR: DNA mismatch repair; RTL: relative telomere length; CRC: colorectal cancer; EC: endometrial cancer; UC: urinary tract cancer; M: male; F: female; in surv: cancer
diagnosed as a consequence of extensive clinical surveillance of LS families.
*Age: Age at cancer diagnosis for cancer-afected carriers, and age at blood draw for cancer-free carriers and non-carriers
**Telchild,Telparent, age-adjusted telomere length is shorter in the child than in the parent. ‘‘Yes’’ indicates that age-adjusted RTL is smaller in the child than in the
parent, therefore indicating association with anticipation when cancer-affected carriers are studied.
***Cancer-free non-carriers are individuals who belong to Lynch syndrome families but do not carry the pathogenic MMR gene mutation.
doi:10.1371/journal.pone.0061286.t003
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Discussion
In this study we found that cancer-affectedMMR gene mutation
carriers have shorter telomeres and faster telomere attrition rates
(accelerated telomere shortening with age) than unaffected
mutation carriers and controls, and that telomere shortening is
not associated with anticipation in the age of cancer onset in
successive generations.
In line of recent retrospective and prospective studies on
sporadic CRC risk and leukocyte telomere length, it has been
suggested that the shorter telomere length observed in retrospec-
tively collected samples from CRC patients is not a cancer risk
factor, but rather a consequence of the disease (from treatment or
disease burden) [16,17]. However, a recent prospective study has
shown that both extremely long and extremely short telomeres
increase CRC risk [18]. In hereditary cases, we observe shorter
telomeres in cancer-affected MMR gene mutation carriers than in
cancer-free carriers, suggesting either that the shortened telomeres
are a result of the disease, or that shorter telomere length is an
additional risk factor for LS patients, i.e. a risk modifier. This is
supported by our recent observation that a variant in the
telomerase gene, hTERT, increases cancer risk in young LS
patients (,45 years of age), as it is associated with shortened
telomeres in cancer-affected MMR gene mutation carriers [11].
Further studies assessing telomere length before and after cancer
diagnosis in CRC patients will provide a definitive answer
regarding the suggested effect of cancer on telomere length in
blood cells. Unfortunately, samples from sporadic CRC cases that
underwent the same DNA extraction and storage than the
hereditary cases and controls herein studied were not available,
precluding a direct comparison. This study will be critical to clarify
whether telomere shortening is specific to cancer-affected LS
patients or if it occurs in all CRC-affected patients.
Our data show longer telomeres in cancer-free MMR gene
mutation carriers compared to cancer-free controls. A plausible
explanation for this observation, and consistent with the fact that
short telomeres act as factors of increased cancer risk, is that longer
telomeres protect MMR gene mutation carriers from developing
cancer. On the other hand, Jones et al. proposed that certain
genetic factors that increase CRC risk may cause longer telomeres
[17]. Alternatively, and in line with this model, our results might
suggest that MMR haploinsufficiency, as a genetic factor of CRC
risk, can exert a lengthening effect on the telomeres. Additional
studies to assess the effect of MMR haploinsufficiency on telomere
lengthening are needed to validate this hypothesis.
We also observed that leukocyte telomere dynamics differ
between cancer-free mutation carriers and cancer-affected carri-
ers, the latter group showing faster telomere shortening with age.
Bozzao et al. found that affected carriers showed accelerated
attrition rate compared to controls [28]. Based on previously
published data on MMR-deficiency and telomeres [29–33], they
suggested that MMR haploinsuffiency in LS individuals may lead
to tolerance of short telomeres, causing faster telomere shortening
over the course of life. However, our results show that this
increased shortening rate does not occur in cancer-free carriers,
thus invalidating the hypothesis. Therefore, this effect may be
either the result of telomere shortening in cancer-affected
individuals, or a marker of increased cancer risk among MMR
gene mutation carriers, supporting the idea that short telomere
length or accelerated telomere attrition rate are factors of
increased cancer risk in LS. Identifying the dynamics of leukocyte
telomere length with age in sporadic cases from retrospective and
prospective studies may resolve this question.
No association was found between the anticipation in the age of
onset observed in successive generations and telomere length. For
years, and despite the numerous reports identifying anticipation in
LS, it was uncertain whether true genetic anticipation contributed
to the early diagnosis age observed in LS. Recently, a Bayesian
method that corrects for random effects, isolating the confounding
effect of changes in secular trends, screening, and medical
practices, and adjusting for changes in age-specific incidence
across birth cohorts, confirmed the anticipation in the age of onset
between successive generations of LS families [10]. Nevertheless,
the molecular mechanism underlying this observation has not
been yet identified. Due to the lack of information on surveillance
time in parents and children, polyp removal, and other
confounding factors, as well as the insufficient sample size for an
accurate assessment of genetic anticipation, it is certain that the
measurement obtained in our series (12 years) is clearly
overestimated. Nevertheless, we accept the results of previous
reports on this matter in which accurate statistical methodologies
were used and anticipation was still confirmed [8–10], and our
series was used to assess the involvement of telomere attrition in
anticipation. Our data rule out the role of telomere shortening in
anticipation in LS. As previously suggested, other molecular
mechanisms such as the accumulation of mismatch repair slippage
events through generations or other genetic or environmental
factors might explain age anticipation in successive generations of
LS families [34,35]. Considering the limitations of our study
regarding sample size, and the inconclusive results obtained when
studying telomere length in cancer patients, further studies on
larger LS series should be performed to validate these results.
Van Vliet et al. recently suggested that CRC risk in carriers of
MMR gene mutations depends on the parent-of-origin of the
mutation. In particular, they suggested a maternally transmitted
mechanism modifying cancer risk in male MMR gene mutation
carriers [36]. Here we observe anticipation associated with shorter
telomeres in all mother-son cancer-affected MMR gene mutation
carriers, whereas the same association is only found in 31% of the
other cancer-affected carrier pair combinations. Although the
sample size of parent-child pairs is very limited, this observation
might suggest that the maternally transmitted risk mechanism is
shortened telomeres. Studies assessing whether telomere shorten-
ing occurs in the female germline, as recently demonstrated in
other mammals [37], together with the analysis of larger samples
of LS parent-child pairs, are required to verify this hypothesis.
In conclusion, our findings indicate that cancer-affected MMR
gene mutation carriers show distinct features and dynamics of
telomere length measured in blood DNA, to controls and
unaffected mutation carriers. While we rule out telomere length
attrition as the common cause of anticipation in LS, it may
account for the dependence of cancer risk on the parent-of-origin
of MMR gene mutations previously observed.
Supporting Information
Figure S1 Age-adjusted RTL distributions in cancer-
affected parents and children with MLH1 and MSH2
gene mutations. The boxes represent the interquartile range of
distributions (25th and 75th percentiles); the horizontal lines within
the boxes, the medians; and the vertical lines, the 5th and 95th
percentiles. Pairwise comparisons using Wilcoxon rank sum test
showed no differences in RTL distributions between cancer-
affected parents and children with germline mutations in MLH1
(p = 0.65), and between parents and children with mutations in
MSH2 (p = 0.67).
(TIF)
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